After halting one GVAX study so it could further investigate a disturbing number of deaths, Cell Genesys' hopes for the vaccine are now focused on a separate Phase III trial that has not raised the same safety concerns. And analysts note that a success in that trial--which provides GVAX alone--could still warrant an approval. In the meantime, shares of Dendreon also traded lower as investors considered the possible implications for all the developers advancing cancer vaccines. Report